摘要
近年来,免疫检查点抑制剂(ICIs)取得了突破性进展,在非小细胞肺癌(NSCLC)的治疗中发挥了重要作用。对于某些免疫应答较强的患者,ICIs常常能取得长期获益。而多项研究显示,表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)与ICIs序贯使用可能导致毒副反应发生率增加。本文综述了EGFR-TKI与ICIs序贯使用的最新研究进展,重点探讨其不良反应的发生情况,以期为EGFR-TKI及ICIs的安全合理使用提供参考。
In recent years,breakthrough has been made in immune checkpoint inhibitors(ICIs),which play an important role in the treatment of NSCLC.ICIs often have long-term benefits for patients with stronger immune responses.Recent studies have shown that the sequential use of EGFR-TKI and ICIs may lead to an increased incidence of toxic effects.This review elaborated the latest research progress in the sequential use of EGFR-TKI and ICIs,focusing on the occurrence of adverse reactions,and providing reference for the safe and rational use of EGFR-TKI and ICIs.
作者
翟婧
严婷
伍奕
陈珊珊
廖德华
ZHAI Jing;YAN Ting;WU Yi;CHEN Shan-shan;LIAO De-hua(Hunan Cancer Hospital,The Affiliated Cancer Hospital of Xiangya School of Medicine,Central South University,Changsha 410031)
出处
《中南药学》
2023年第7期1865-1870,共6页
Central South Pharmacy
基金
湖南省自然科学基金项目(No.2021JJ70025)
湖南省医学会临床药学分会基金项目(No.HMA202001005)
湖南省药学会基金项目(No.2020YXH001)
湖南省肿瘤医院攀登基金项目(No.2021NSFC-A003)。
关键词
非小细胞肺癌
EGFR-TKI
免疫检查点抑制剂
序贯使用
不良反应
non-small cell lung cancer
epidermal growth factor receptor-tyrosine kinase inhibitor
immune checkpoint inhibitor
sequential use
adverse reaction
